Pub. Date : 2020 Nov
PMID : 32871626
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The tyrosine kinase inhibitors (TKIs), crizotinib, lorlatinib, and entrectinib have demonstrated favorable efficacy in treating ROS1-rearranged NSCLCs. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | ROS1 mutations, including G2032R were observed in approximately 33% of post-crizotinib samples. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 3 | Collectively, we report the prevalence of ROS1 fusions in a large-scale NSCLC population, and the efficacy of crizotinib in treating patients with ROS1-rearranged NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |